Overview

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the safety and tolerability when adding abatacept to acute Graft versus Host Disease in transplants for malignant diseases using unrelated donor bone marrow or peripheral blood stem cell grafts.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Children's Hospital
Emory University
Treatments:
Abatacept